Post date
05/02/2018
- Syndesi Therapeutics to leverage UCB’s expertise in neurology drug discovery to develop potential therapeutics in cognitive disorders with a first-in-class mechanism
- Series A financing of €17 M
Louvain-la-Neuve, 26th June 2017 - Aphea.Bio, spin-off of the VIB, UGent and KU Leuven, will develop sustainable agricultural products based on nature-based microorganisms to increase crop yield and